BRIEF published on 04/30/2024 at 11:05, 1 year 7 months ago New Partnership Between BioMed X Institute and Merck Focuses on Immuno-Oncology Cancer Research BioMed X Institute Immunotherapy Merck Tumor Immunogenicity
PRESS RELEASE published on 04/30/2024 at 11:00, 1 year 7 months ago New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg Biomedical research institute, BioMed X, partners with Merck to develop novel immunotherapeutic strategies to enhance tumor immunogenicity for cancer patients Cancer Research Immunotherapy Merck Tumor Immunogenicity BioMed X
PRESS RELEASE published on 02/06/2024 at 16:00, 1 year 9 months ago New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine BioMed X Institute and Universitatsmedizin Mannheim researchers publish results of collaboration on new neoepitope vaccine in diffuse midline glioma in Science Advances BioMed X Institute Universitatsmedizin Mannheim Neoepitope Vaccine Diffuse Midline Glioma Science Advances
PRESS RELEASE published on 11/07/2023 at 12:00, 2 years ago BioMed X Launches a New Call for Application in Autoimmune Disease Research
PRESS RELEASE published on 10/31/2023 at 17:00, 2 years 1 month ago BioMed X and AbbVie Start New Research Project in the USA
PRESS RELEASE published on 06/29/2023 at 11:00, 2 years 5 months ago BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
PRESS RELEASE published on 04/27/2023 at 14:00, 2 years 7 months ago BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim - a New Model for Building an External Innovation Ecosystem on an Industry Campus
PRESS RELEASE published on 04/04/2023 at 11:00, 2 years 8 months ago BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Published on 12/05/2025 at 02:35, 4 hours 59 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 34 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 29 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 34 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 34 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 4 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 43 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 9 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 19 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 20 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 34 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 34 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 49 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 49 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
